NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
Press Release
Read More
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Press Release
Read More
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
Press Release
Read More
Circulating tumor DNA (ctDNA) monitoring in breast cancer patients receiving neoadjuvant palbociclib and endocrine therapy. A secondary analysis of the NeoRHEA phase 2 study
Literature
Read More